CMS Blocks $1.6 Billion in Fraudulent Medicare Lab Billing

Full analysis

The Centers for Medicare & Medicaid Services (CMS) announced it has stopped more than $1.6 billion in potentially improper Medicare laboratory payments since the start of 2025, including $732 million saved by revoking 157 fraudulent lab providers, over $500 million in payments suspended from 185 labs under investigation, $276 million recouped from identified overpayments, and $127 million prevented through law enforcement referrals. CMS is using artificial intelligence and machine-learning models to scan Medicare claims for unusual billing patterns — such as labs billing for tests never performed, services billed to patients with no relationship to the ordering provider, and inflated billing codes — across areas including genetic testing, drug testing, and pathogen detection.

For Medicare beneficiaries, the practical concern is that this kind of fraud drains the Medicare Trust Fund, which ultimately affects program resources. CMS reports that in fiscal year 2025 alone, its fraud-prevention efforts produced a record $42 billion in savings across Medicare. In 2026, the agency says it has already identified $1.8 billion in overpayments and suspended more than $539 million in suspected fraudulent payments. Beneficiaries who receive Explanation of Benefits statements showing lab tests they do not recall having should report discrepancies to CMS, as fraudulent billing in their name can affect their records.